Learn · regulatory literacy

What is FDA enforcement discretion?

Enforcement discretion is the FDA announcing it will temporarily not act against something that technically violates the rules - usually for a practical reason like a drug shortage. The rule itself never changes. That is why a product can feel legal for a year and then "become illegal" overnight: the violation was there all along, and what ended was the agency's stated decision to look away.

Published Aug 21, 2026 (ET) · every claim sourced below

How it works, using the GLP-1 case

The clearest recent example is compounded semaglutide. Copying an approved drug is normally prohibited - but during the declared shortage, compounding copies was permitted, and the FDA also exercised discretion during the wind-down period after the shortage was declared resolved in February 2025. Those grace periods ended on fixed dates (April 22, 2025 for 503A pharmacies; May 22, 2025 for 503B facilities), and the underlying prohibition simply resumed being enforced. The full timeline is here.

The lesson generalizes: when you read that the FDA "is allowing" something in this space, the precise question to ask is whether a rule changed or an enforcement posture did. A rule change goes through the Federal Register and is durable. An enforcement posture is a policy statement that can end - sometimes with notice and a wind-down schedule, sometimes simply when conditions change.

Why a status tracker treats it specially

For a reference like this one, enforcement discretion is the trickiest state to report honestly: the law says one thing, practice temporarily says another, and both are true. Peptlas handles it by reporting the rule as the status and the discretion as dated context - so a wind-down date never arrives as a surprise. Every entry's what changed last section records these shifts with their primary sources, and the alert list sends exactly one email when one moves.

Current statuses mentioned here

Asked and answered

Is something under enforcement discretion legal?
The underlying activity still violates the rule - the agency has just said it will not act for now. It is a temporary posture, not a legal authorization, and it can end on a schedule or abruptly.
How do I know if a permission is real or just discretion?
Real changes go through rulemaking and publish in the Federal Register. Discretion arrives as FDA guidance, policy statements, or shortage-list mechanics. If you cannot find a rule change, assume you are looking at discretion.
Did the FDA use enforcement discretion for peptides like BPC-157?
The GLP-1 shortage case is the clean example of formal discretion. For research-chemical peptides the situation is different - there is no announced discretion policy; enforcement is simply prioritized against manufacturers and sellers making drug claims, which is a resource choice rather than a stated policy.

Sources

Keep going

Why is compounded semaglutide going away?Why are peptides sold "for research use only"?All learn articlesThe full atlas